Group manager: Marc Wilkinson
The team covers a full spectrum of biotechnological and biomedical subject areas.
In addition to a core prosecution practice, the group thrives in tackling difficult legal questions, particularly in the context of post-grant contentious proceedings. This effective formula has led to a track record in obtaining successful results, often where others have failed.
We have been contributing to European biotech case law for many years. Early successes included the famous “Harvard Oncomouse” case. More recently, the “Zcytor1” case before the Technical Board of Appeal of the European Patent Office, described as “seminal” by the English Court of Appeal, set new standards in the patentability of biotech subject-matter.
Our experience range is broad. We handle cutting-edge technologies, but always with a strong commercial focus.
Technology group areas
- High affinity antibodies
- Humanised antibodies
- Antibody-based assays and diagnostics
- Antibody-based therapeutics
- Antibody engineering
- Phage display, for example of multichain proteins
- RNAi gene expression control
- Oligonucleotide arrays and screening using same
- Molecular array technology
- Diagnostic assays and test kits, for example lateral flow test strip technology
- Diagnostic devices and reagents
- Medical devices, for example drug-coated segmental stents
- Microfluidic devices, for example biochips
- Virus and vaccine engineering, for example adenovirus based vaccines
- Molecular probes and probing technologies
- Gene activation
- Human telomerase and cancer vaccination
- Biochemistry and pharmaceutical development
- Energetics and metabolic processes
- Cardiac disease and diagnosis of same, for example echocardiography
- HPV-induced disease biology
- Nucleic acid extraction and amplification
- PCR, for example PCR-based assay technology